Recent News

• 08.06.2026 - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
• 08.06.2026 - Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
• 07.30.2026 - Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
• 07.21.2026 - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
• 07.16.2026 - Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026
• 07.13.2026 - Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
• 07.06.2026 - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
• 06.22.2026 - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
• 06.04.2026 - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
• 06.03.2026 - Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026

Recent Filings

• 07.30.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.30.2026 - 8-K Current report
• 07.30.2026 - EX-99.1 EX-99.1
• 07.29.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.20.2026 - 144 Report of proposed sale of securities
• 06.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.18.2026 - 4 Statement of changes in beneficial ownership of securities